Infection prevention
First author Sanz-Codina Gatti
Abdul-Azis Sime Hagel
Year Type of study
2023 Meta-analysis (RCT) 2024
Meta-analysis (RCT and observational)
2024 Meta-analysis (RCT)
2015 RCT 2022 RCT
Delhunty (BLING III) 2024 RCT
De Waele Roberts
Mckinnon Balakrishnan 2014 RCT
2014 Prospective 2008 Retrospective 2011
Retrospective
No. 1241
Antibiotic/approach
4833 Aggressive PKPD i.e. 4x t>MIC
Outcome
Individualised dosing (TDM) Trend to lower mortality but not significant Higher clinical cure; lower resistance rates
9108 Beta-lactam delivery 32
254
Beta-lactams (TDM) Tazocin (TDM)
703 Beta-lactams delivery 41 Beta-lactams (TDM)
384 Beta-lactams 76 92
Cefipime/ceftazidime Beta-lactam dosing
Lower mortality with prolonged vs intermittent infusion No difference in days to recovery
Trend to lower mortality but not significant
Trend to lower mortality with continuous infusion vs intermittent but not significant
No clinical difference (but improved antibiotic target attainment) Longer T>MIC had better clinical outcome Longer T>MIC had better clinical outcome Optimised dose improved clinical efficacy
Table 1: Summary of evidence: the green colour represents studies that have favourable results for optimising dosing and clinical outcomes i.e. reduced mortality/higher clinical cure. The orange shows a trend or positive signal towards an improved outcome with optimal dosing. The grey shows no clinical difference. Overall, the literature suggests that under-delivery or under-dosing of antibiotics is not good for patients.
Routine line flushing enables oncology to give multiple different doses through the same administration set line. In all other areas, the administration set is discarded with the residual volume contained. Claire Davies argued that all patients should get the same standard of care. She went on to look at the impact of this under delivery of antibiotics: “Data shows that nine oil tankers of IV antibiotics that should be infused into patients are discarded each year, instead of supporting the fight against infections. These antibiotics could find their way into the water system or landfill, and contribute to our global AMR crisis,” she warned. Claire Davies moved on to discuss the
available guidance. NIVAS published line flushing guidance in 2021, which states: “All the prescribed medicine should be administered.” NIVAS outlined two methods to achieve this: l Method one: The saline bag l Method two: Administration set with injection port above the drip chamber.
“If you use method one, it is important to ensure you use an administration set with an air stop filter, to prevent air entering the system. If there is air in the system, you cannot follow with your flush. It is also important to show slight caution with regard to the risk of fluid overload to your patient.
“Method two involves selecting an IV administration set also with an air stop filter, but this also has a needle-free access above the drip chamber. So, this time, when the drug bag and the drip chamber empty, the fluid level will stop just below the drip chamber – allowing us, as clinicians, to add a small volume flush with a syringe to the drip chamber. That flush will then
follow the drug and flush the remainder of the drug into the patient…delivering the full dose,” she explained. Following the NIVAS publication in 2021,
several other influential bodies followed suit, which included the All-Wales Guidance on flushing IV administration sets, the Royal Marsden Manual of Clinical Nursing Procedures, and the Infusion Therapy Standards of Practice. “All of these explicitly state we should be flushing our intermittent infusion sets in order to deliver the full dose to our patients,” Claire Davies explained. Dr. Emma Baldock, a Consultant Microbiologist
at Sheffield Teaching Hospitals NHS Trust, went on to discuss ‘why under-delivery of antibiotics is a problem in clinical practice’. She described the basic “bug-drug principles”,
which included: l Pharmacokinetics (PK) – what the body does to the drug i.e. absorbs, metabolises, eliminates.
l Pharmacodynamics (PD) – what the drug does to the body i.e. effects at a cellular level.
l Minimum inhibitory concentration (MIC) - lowest concentration of the antibiotic that prevents the bug growing.
l Clinical breakpoints are threshold used to decide if an antibiotic will work against an infection, which requires complex collaborative decisions.
l Antibiotic doses given by e.g. EUCAST (European Committee on Antimicrobial Susceptibility Testing) give reassurance that ‘sensitive’ bacteria will be treated.
Her take-home message was that “we need to ensure antibiotics are used to their maximum
potential” and that we need to “give the right dose if we expect to achieve good clinical outcomes.” However, there is very little measurement of antibiotic levels in routine clinical practice. It is mainly done to rule out toxicity rather than help guide success and can be challenging to achieve in ‘real-time’. “For example, for Vancomycin, you need to
take a blood level immediately before a dose and possibly for Gentamicin a set time after a dose – so, that’s quite precise nursing time required, in order to achieve an accurate level. Often, there’s a ward full of patients, with competing priorities… “The other issue is that our laboratories are
often decoupled from our hospital. Therefore, you’ve got to get the blood sample to your laboratory, so it can be processed and analysed; then a clinician or prescriber has to come and change the dose to make it bespoke for that patient,” Dr. Baldock pointed out. She added that: “Often antibiotic levels in the body and the effect on the ‘bugs’ is fairly blind”, so microbiological and clinical parameters are used to know if a patient is responding. She highlighted three ways to improve antibiotic delivery: l Therapeutic drug monitoring (TDM). l Prolonged/continuous antibiotic infusions (BLING III study/meta-analysis) – get to the right dose and keep it there.
l Ensure the full intended dose is given i.e. flush administration set after each dose – this is surprisingly not often done in the NHS.
She described the latter solution as a “no brainer”, yet national surveys have indicated that only around 30% of hospitals are currently doing
September 2026 I
www.clinicalservicesjournal.com 29
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85